

**PE/Dazzle™ 594 anti-mouse CD49b (pan-NK cells)**

**Catalog # / Size:** 1144620 / 100 µg  
1144615 / 25 µg

**Clone:** DX5

**Isotype:** Rat IgM, κ


**Immunogen:** IL-2-propagated NK1.1+ cells from C57BL/6 mice

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** Lot-specific



C57BL/6 mouse splenocytes were stained with NK1.1 Alexa Fluor® 647 and CD49b (clone DX5) PE/Dazzle™ 594.

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.175 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

\* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen *in vitro*. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity<sup>2</sup> and immunohistochemical staining<sup>5</sup> of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections<sup>10</sup>. The binding of DX5 antibody to splenic NK cells can be blocked by HMA2 antibody.

- Application References:**
1. Arase H, *et al.* 2001. *J. Immunol.* 167:1141. (FC)
  2. Sepulveda H, *et al.* 1999. *J. Immunol.* 163:1133.
  3. Norian LA and Allen PM. 2004. *J. Immunol.* 173:835. (FC)
  4. Andoniou CE, *et al.* 2005. *Nature Immunology* 6:1011.
  5. Oertelt S, *et al.* 2006. *J. Immunol.* 177:1655. (IHC) [PubMed](#)
  6. Bourdeau A, *et al.* 2007. *Blood* doi:10.1182/blood-2006-08-044370.

7. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  8. Qui Q, *et al.* 2010. *J. Immunol.* 184:1681. (FC) [PubMed](#)
  9. Busche A, *et al.* 2011. *J. Immunol.* 186:2918. [PubMed](#)
  10. Kim HR, *et al.* 2011. *Nephrology* 16:545. (IHC) [PubMed](#)
  11. Seyoum B, *et al.* 2011. *Vaccine.* 29:8002. [PubMed](#)
  12. Younos IH, *et al.* 2012. *Int Immunopharmacol.* 13:245. [PubMed](#)
  13. Honjo K, *et al.* 2012. *PNAS.* [PubMed.](#)
  14. Huang HN, *et al.* 2013. *Biomaterials.* 34:10151. [PubMed](#)
- 

**Description:** DX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin  $\alpha$  chain also known as  $\alpha_2$  integrin, VLA-2  $\alpha$  chain, and integrin  $\alpha_2$  chain. CD49b non-covalently associates with CD29 ( $\beta_1$  integrin) to form the CD49b/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.

- Antigen**
- References:**
1. Arase H, *et al.* 2001. *J. Immunol.* 167:1141.
  2. Barclay AN, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
  3. Sasaki K, *et al.* 2003. *Int. Immunol.* 15:701.
  4. Inoue O, *et*